# A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent

> **NCT02046603** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 162 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** DMARDs
- **DRUG:** Oral Corticosteroids
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02046603
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-04
- **Primary completion:** 2016-08-04
- **Final completion:** 2016-08-04
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2018-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02046603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02046603, "A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02046603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*